Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Active-Controlled, Open-Label Phase IIb Study Evaluating Safety and Tolerability of Switching to Zovaglutide Injection After Titration to 2.4 mg Semaglutide Injection (Wegovy®) in Adults With Obesity (HORIZON-SWITCH-SZ)

NCT07812597 is registered in ClinicalTrials.gov with Beijing QL Biopharmaceutical Co.,Ltd as lead sponsor.

NCT NCT07812597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07812597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Active-Controlled, Open-Label Phase IIb Study Evaluating Safety and Tolerability of Switching to Zovaglutide Injection After Titration to 2.4 mg Semaglutide Injection (Wegovy®) in Adults With Obesity (HORIZON-SWITCH-SZ)
Lead sponsor
Beijing QL Biopharmaceutical Co.,Ltd
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 12, 2026
Completion date
March 24, 2028
Enrollment
210 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

obesity